Background: Variable rates of HER2 protein overexpression and gene amplification have been reported in advanced ovarian cancers (AOC). Trastuzumab, tested only as a single agent, has been shown to ...

Triple negative breast cancer accounts for 15% of cases but causes a disproportionate number of deaths. Learn about symptoms ...

In addition to determining the hormone receptor and HER2 protein status, healthcare teams use the TNM system to identify the stages. This system notes: Your oncologist will use scoring of these ...

Patients with certain subtypes of breast cancer may face a higher risk of death from the cancer if they wait more than 42 ...

Scientists at King’s College London have developed an innovative IgE antibody therapy that activates the immune system to ...

Patients with certain subtypes of breast cancer may face a higher risk of death from the cancer if they wait more than 42 ...

Vepdegestrant is a novel proteolysis targeting chimera protein degrader designed to target and degrade the estrogen receptor.

Antibody-drug conjugates have had a tremendous impact on breast cancer care and treatment, according to Dr. Charles E. Geyer.

The FLAMINGO-01 DSMB met twice in 2024, most recently in December 2024, and recommended to continue the study as is without modification. No serious adverse events related to GLSI-100 have been ...

OS Therapies (NYSE-A: OSTX) ("OS Therapies" or "the Company"), a clinical-stage immunotherapy and Antibody Drug Conjugate (ADC) biopharmaceutical company, today announced that OST-HER2 is featured in ...